Mainz Biomed BV

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q3 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Mainz Biomed NV is a molecular genetics cancer diagnostic company. The firm is engaged in the developing of market-ready molecular genetic diagnostic solutions for life-threatening conditions. It is involved in the commercializing of its product portfolio in Europe, the United States, and the rest of world. The company was founded on March 08, 2021 and is headquartered in Mainz, Germany.

BERKELEY, US and MAINZ, Germany , Jan. 03, 2023 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, announced today a corporate summary for the fiscal year ended December 31, 2022.

Mainz Biomed Provides Year-End 2022 Corporate Review

BERKELEY, Calif. and MAINZ, Germany, Dec. 20, 2022 (GLOBE NEWSWIRE) -- Mainz Biomed NV (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, announced today the first patient has been enrolled in eAArly DETECT, Mainz's U.S. extension of ColoFuture, its European feasibility study evaluating the integration of a portfolio of novel gene expression (mRNA) biomarkers into ColoAlert. Currently, Mainz is commercializing ColoAlert, its highly efficacious, and easy-to-use detection test for colorectal cancer (CRC) across Europe and in select international territories. ColoFuture/eAArly DETECT are multi-center studies assessing the potential of these biomarkers to identify advanced adenomas, a type of pre-cancerous polyp often attributed to CRC.

Mainz Biomed Enrolls First Patient in eAArly DETECT Study Evaluating Integration of Novel mRNA Biomarkers into ColoAlert

BERKELEY, Calif. and MAINZ, Germany, Dec. 06, 2022 (GLOBE NEWSWIRE) -- Mainz Biomed NV (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, announced today that it has received approval from an independent Institutional Review Board (IRB) for the protocol ReconAAsense, the Company's U.S. pivotal study to evaluate the clinical performance of its highly efficacious and easy-to-use detection test for colorectal cancer (CRC). Mainz Biomed will now initiate the study, which will form the basis of the data package to be submitted for review by the U.S. Food and Drug Administration (FDA) to achieve marketing authorization.

Mainz Biomed Announces IRB Approval and Initiation of US Pivotal FDA Clinical Study

Former Roche executive Amy Levin, RAC, brings more than 20 years of regulatory affairs experience as an in vitro diagnostics (IVD) industry leader Former Roche executive Amy Levin, RAC, brings more than 20 years of regulatory affairs experience as an in vitro diagnostics (IVD) industry leader

Mainz Biomed Appoints Amy Levin as Vice President of Regulatory Affairs to Oversee Global Regulatory Strategies

BERKELEY, Calif. and MAINZ, Germany, Nov. 22, 2022 (GLOBE NEWSWIRE) -- Mainz Biomed NV (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, announced today that members of its executive team will be participating in two notable conferences in November and December 2022, Deutsches Eigenkapitalforum 2022 and Cantor Fitzgerald's Medical & Aesthetic Dermatology, Ophthalmology & MedTech Conference.

Mainz Biomed to Participate in Deutsche Eigenkapitalforum and Cantor Fitzgerald's Medical & Aesthetic Dermatology, Ophthalmology & MedTech Conference

BERKELEY, Calif. and MAINZ, Germany, Nov. 15, 2022 (GLOBE NEWSWIRE) -- Mainz Biomed NV (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, announced today the initiation of eAArly DETECT, its U.S. extension of ColoFuture, the Company's European feasibility study evaluating the integration of a portfolio of novel gene expression (mRNA) biomarkers into ColoAlert, Mainz's highly efficacious, and easy-to-use detection test for colorectal cancer (CRC) being commercialized across Europe and in select international territories. ColoFuture/eAArly DETECT are multi-center studies assessing the potential of these biomarkers to identify advanced adenomas, a type of pre-cancerous polyp often attributed to CRC.

Mainz Biomed Announces U.S. Extension of ColoFuture Study to Evaluate Integration of Novel mRNA Biomarkers into ColoAlert

BERKELEY, Calif. and MAINZ, Germany, Nov. 02, 2022 (GLOBE NEWSWIRE) -- Mainz Biomed NV (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer today provided an update on accomplishments during the third quarter which ended September 30, 2022.

Mainz Biomed Provides Third Quarter 2022 Update

Mainz Biomed is a German developer of genetic tests for various diseases, primarily cancer. At the moment, the company has one main product, ColoAlert, a colorectal cancer test that is so far only approved in some non-US countries.

Mainz Biomed: A Long-Term Bet Relying On Expanded Testing

Dr. Dreismann, Former Roche Molecular Diagnostics CEO, and Mr. Tibbitts, a Highly-accomplished Life-Sciences Executive, Provide Extensive Experience in Diagnostics and Financial Strategy

Mainz Biomed Strengthens Board of Directors with Nomination of Dr. Heiner Dreismann and Gregory Tibbitts

BERKELEY, Calif. and MAINZ, Germany, Sept. 20, 2022 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, announced today the appointment of Dr. Douglas K. Rex to its Medical Advisory Board (MAB). Dr. Rex is the latest industry expert to join the MAB which was established to support Mainz's forthcoming U.S. pivotal trial for ColoAlert, the Company's highly efficacious, and easy-to-use detection test for colorectal cancer (CRC).

Mainz Biomed Appoints Dr. Douglas Rex to its Medical Advisory Board

BERKELEY, Calif. and MAINZ, Germany, Sept. 07, 2022 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, announced today financial results for the first half of the fiscal year ended June 30, 2022.

Mainz Biomed Reports First Half 2022 Financial Results

BERKELEY, Calif. and MAINZ, Germany, Sept. 01, 2022 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, announced today that Bill Caragol, Chief Financial Officer, will present at the H.C. Wainwright Annual Global Investment Conference taking place from September 12-14, 2022.

Mainz Biomed to Present at the H.C. Wainwright Annual Global Investment Conference

BERKELEY, Calif. and MAINZ, Germany, Aug. 23, 2022 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, announced today the appointment of Dr. D. Kim Turgeon of University of Michigan Health to its Medical Advisory Board (MAB).

Mainz Biomed Appoints Dr. D. Kim Turgeon of University of Michigan Health to its Medical Advisory Board

– ColoAlert to be marketed through Dante's extensive database and sold via its region-specific, ecommerce websites – – ColoAlert to be marketed through Dante's extensive database and sold via its region-specific, ecommerce websites –

Mainz Biomed and Dante Genomics Announce Full Commercial Availability of ColoAlert in Italy and the United Arab Emirates

Dr. Frank Krieg-Schneider to lead development across Mainz Biomed's portfolio of advanced cancer detection products including its flagship product ColoAlert and future diagnostic tests Dr. Frank Krieg-Schneider to lead development across Mainz Biomed's portfolio of advanced cancer detection products including its flagship product ColoAlert and future diagnostic tests

Mainz Biomed Appoints Former QIAGEN Executive Dr. Frank Krieg-Schneider as Vice President of Development

BERKELEY, Calif. and MAINZ, Germany, July 19, 2022 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, announced today the formation of a Medical Advisory Board (MAB), and the appointment of Dr. Timothy Wang as its inaugural member. The MAB will support the Company's forthcoming U.S. pivotal trial for ColoAlert, its highly efficacious, and easy-to-use detection test for colorectal cancer (CRC) and assist Mainz in evaluating ColoAlert's potential to address additional oncology indications along with enhancing Mainz's pipeline of product candidates.

Mainz Biomed Appoints Dr. Timothy Wang to Newly Formed Medical Advisory Board

Company to Host Webcast Today - July 12th - at 4.00pm ET Company to Host Webcast Today - July 12th - at 4.00pm ET

Mainz Biomed Today to Provide Corporate Update for First Half of 2022

Company to Host Webcast on July 12 at 4.00pm ET Company to Host Webcast on July 12 at 4.00pm ET

Mainz Biomed Provides Corporate Update for First Half of 2022

BERKELEY, Calif. and MAINZ, Germany, June 28, 2022 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, announced today it has enrolled the first patient in ColoFuture, an international clinical study assessing the potential to integrate a portfolio of novel gene expression (mRNA) biomarkers into ColoAlert, the Company's highly efficacious, and easy-to-use detection test for colorectal cancer (CRC) which is being commercialized across Europe.

Mainz Biomed Enrolls First Patient in ColoFuture Study Evaluating Integration of Novel mRNA Biomarkers into ColoAlert

Jane Edwards, CCRA, RAC brings over 20 years of senior experience developing optimal product and clinical trial strategies in diagnostics and medical devices

Mainz Biomed Appoints Vice President of Clinical Affairs to Lead US Clinical Studies in Support of FDA Submission

New and stringent EU regulation on in vitro diagnostic medical devices sets a higher standard of quality and safety for in vitro diagnostic (IVD) products and manufacturer process New and stringent EU regulation on in vitro diagnostic medical devices sets a higher standard of quality and safety for in vitro diagnostic (IVD) products and manufacturer process

Mainz Biomed Successfully Completes Conformity Assessment to IVDR Achieving New Level of EU Regulatory Compliance

BERKELEY, Calif. and MAINZ, Germany and NEW YORK, May 19, 2022 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer and Dante Labs, a global leader in genomics and precision medicine, announced today a partnership for the commercialization of ColoAlert in Italy and the United Arab Emirates (UAE). ColoAlert is Mainz's flagship product, a highly efficacious and easy to use at-home detection test for colorectal cancer (CRC).

Mainz Biomed & Dante Labs Announce Partnership for the Commercialization of ColoAlert in Europe and the United Arab Emirates (UAE)

BERKELEY, Calif. and MAINZ, Germany, May 17, 2022 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, announced today that members of its executive team will be participating in two notable investor conferences in May, 2022, the H.C. Wainwright Global Investment Conference and the Equity Forum German Spring Conference.

Mainz Biomed to Participate in H.C. Wainwright Global Investment Conference and Equity Forum German Spring Conference

BERKELEY, Calif. and MAINZ, Germany, May 09, 2022 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, announced today that it will bring together key opinion leaders (KOLs) from across the Colorectal Cancer (CRC) screening and diagnostics community in an event to be held during Digestive Disease Week (DDW 2022) in San Diego, California.

Mainz Biomed to Host Key Opinion Leader Event at DDW 2022

BERKELEY, Calif. and MAINZ, Germany, May 05, 2022 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, announced today that PancAlert, its screening test candidate for pancreatic cancer has achieved multiple pre-clinical milestones that support the development of this potential first-in-class diagnostic for a deadly cancer indication.

News for Mainz Biomed BV Stock (MYNZ)